Segment & Geographic Data
Quant-Grade Normalized Data
API & CSV Delivery
Pear Therapeutics Inc's Business Segments
Pear Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
-
Largest Segment
-
Total Revenue
-
Regions Reported
-
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/PEAR/segments
https://api.csimarket.com/api/v1/companies/PEAR/geographic
https://api.csimarket.com/api/v1/companies/PEAR/exposure
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Connect Your AI Assistant
Annual Results
Revenue by Product & Service Category -
- Product82.1%
- Subscription, Support, and Professional Services Revenue11.1%
- Collaboration and License Revenue6.9%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 10 | 82.1% |
| Subscription, Support, and Professional Services Revenue | $ 1 | 11.1% |
| Collaboration and License Revenue | $ 1 | 6.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Pear Therapeutics Inc
Pear Therapeutics Inc is a digital therapeutics company that develops clinically validated software applications to treat a wide range of medical conditions, particularly in the field of mental health and addiction. The company was founded in 2013 by Corey McCann, Eddie Martucci, and Yuri Maricich, with the aim of leveraging technology to improve patient outcomes and reduce healthcare costs.
Pear Therapeutics focuses on developing prescription digital therapeutics (PDTs) that are designed to be used in conjunction with pharmaceutical treatments to enhance their efficacy. PDTs are software programs that deliver evidence-based interventions to patients through digital devices such as smartphones or tablets. These interventions are tailored to the specific needs of each patient and are designed to improve engagement and adherence to treatment plans.
One of the notable products developed by Pear Therapeutics is reSET, which is the first FDA-approved PDT for the treatment of substance use disorder. reSET is a 12-week program that provides cognitive-behavioral therapy and contingency management techniques to patients, helping them to develop and maintain abstinence from substances. The software collects patient data to track progress and provide feedback to both the patient and their healthcare provider.
Another product developed by Pear Therapeutics is reSET-O, which is the first FDA-approved PDT for the treatment of opioid use disorder. reSET-O combines medication-assisted treatment with cognitive-behavioral therapy delivered through a mobile application. It helps patients adhere to their medication regimen and provides behavioral therapy techniques to support recovery.
Pear Therapeutics' products are based on rigorous clinical trials and have demonstrated efficacy in improving patient outcomes. The company has a team of scientists, engineers, clinicians, and software developers who collaborate to develop these innovative solutions. Their products are designed to be user-friendly, accessible, and scalable, allowing a wide range of patients to benefit from digital therapeutics.
Aside from their addiction treatment products, Pear Therapeutics is also developing PDTs for other mental health disorders, including schizophrenia, major depressive disorder, and post-traumatic stress disorder. They have partnerships with pharmaceutical companies to combine their digital therapeutics with existing pharmaceutical treatments to provide comprehensive patient care.
The company is headquartered in Boston, Massachusetts, and has additional offices in San Francisco, California, and Durham, North Carolina. Pear Therapeutics has received recognition for their groundbreaking work in the field of digital therapeutics, including being named Healthcare Technology of the Year by Fast Company in 2018 and being included in the Top 10 Most Innovative Companies in Health by Fast Company in 2020.
Pear Therapeutics focuses on developing prescription digital therapeutics (PDTs) that are designed to be used in conjunction with pharmaceutical treatments to enhance their efficacy. PDTs are software programs that deliver evidence-based interventions to patients through digital devices such as smartphones or tablets. These interventions are tailored to the specific needs of each patient and are designed to improve engagement and adherence to treatment plans.
One of the notable products developed by Pear Therapeutics is reSET, which is the first FDA-approved PDT for the treatment of substance use disorder. reSET is a 12-week program that provides cognitive-behavioral therapy and contingency management techniques to patients, helping them to develop and maintain abstinence from substances. The software collects patient data to track progress and provide feedback to both the patient and their healthcare provider.
Another product developed by Pear Therapeutics is reSET-O, which is the first FDA-approved PDT for the treatment of opioid use disorder. reSET-O combines medication-assisted treatment with cognitive-behavioral therapy delivered through a mobile application. It helps patients adhere to their medication regimen and provides behavioral therapy techniques to support recovery.
Pear Therapeutics' products are based on rigorous clinical trials and have demonstrated efficacy in improving patient outcomes. The company has a team of scientists, engineers, clinicians, and software developers who collaborate to develop these innovative solutions. Their products are designed to be user-friendly, accessible, and scalable, allowing a wide range of patients to benefit from digital therapeutics.
Aside from their addiction treatment products, Pear Therapeutics is also developing PDTs for other mental health disorders, including schizophrenia, major depressive disorder, and post-traumatic stress disorder. They have partnerships with pharmaceutical companies to combine their digital therapeutics with existing pharmaceutical treatments to provide comprehensive patient care.
The company is headquartered in Boston, Massachusetts, and has additional offices in San Francisco, California, and Durham, North Carolina. Pear Therapeutics has received recognition for their groundbreaking work in the field of digital therapeutics, including being named Healthcare Technology of the Year by Fast Company in 2018 and being included in the Top 10 Most Innovative Companies in Health by Fast Company in 2020.
Pear Therapeutics Inc. specializes in the development of digital therapeutics, which are software-based interventions designed to treat various medical conditions. The company has pioneered the integration of digital solutions with traditional therapies, specifically focusing on the treatment of substance use disorders and other mental health conditions. Below are extensive descriptions of their segments, products, and services.
Segments
1. Digital Therapeutics for Substance Use Disorders (SUD)
- Pear Therapeutics is particularly known for its innovative approaches to treating substance use disorders. The company utilizes prescription digital therapeutics (PDTs) that can be integrated into traditional care, thereby improving clinical outcomes.
2. Mental Health and Behavioral Disorders
- Beyond substance use disorders, Pears portfolio extends into other areas of mental health, focusing on conditions such as depression and anxiety. Through their digital platforms, they offer behavioral interventions that can complement pharmacological treatments.
3. Regulatory and Clinical Development
- The company is involved in the rigorous clinical testing of its digital products to ensure they meet the necessary regulatory standards. This segment is crucial for gaining FDA approval and other regulatory clearances, enabling the products to be prescribed by healthcare professionals.
Products
1. reSET®
- This is one of Pears flagship products, aimed at treating patients with substance use disorders. reSET is a prescription digital therapeutic that helps patients engage in cognitive behavioral therapy (CBT) and supports recovery through contingency management and continuous connectivity with healthcare providers. It is designed to be used alongside other treatments, such as counseling or medication.
2. reSET-O®
- Similar to reSET, reSET-O is specifically designed for patients suffering from Opioid Use Disorder (OUD). It is intended to provide prescription-level support as part of a comprehensive treatment plan, including medication-assisted treatment (MAT). reSET-O facilitates engagement and allows providers to monitor patient progress through data collected by the software.
3. Pears Digital Therapeutics for Depression
- The company is actively developing products targeted at depression, utilizing evidence-based therapeutic techniques that are delivered through an app-based platform. These digital therapeutics focus on self-management of symptoms and adherence to treatment plans.
4. Next-Generation Digital Therapeutics
- Pear is also exploring further innovations in its product pipeline, which may include therapies for anxiety, insomnia, and other behavioral health conditions. These products are expected to incorporate advanced therapeutic techniques and personalized feedback mechanisms to enhance user experience and engagement.
Services
1. Patient Support Programs
- Pear Therapeutics offers support services to patients using their digital therapeutics. These programs typically include educational resources, reminders for therapy engagement, and access to peer support groups, all designed to enhance the recovery journey.
2. Healthcare Provider Training
- To ensure that healthcare providers can effectively incorporate Pears digital therapeutics into their treatment plans, the company provides training and resources. This service allows healthcare professionals to better understand digital therapies, how to use them alongside traditional treatments, and how to engage with patients effectively.
3. Data Analytics and Reporting
- Pears products often include robust data collection and analytics features that allow healthcare providers to monitor patient progress and treatment engagement effectively. This service can be critical for tailoring treatments and interventions to individual patient needs.
4. Integration with EHR Systems
- Pear is also focused on enabling its therapeutic platforms to integrate seamlessly with electronic health records (EHR) systems. This integration supports the holistic management of patient care and ensures that healthcare providers can easily access relevant data.
Conclusion
Pear Therapeutics Inc. stands at the forefront of the digital therapeutics industry, developing innovative products that transform the treatment landscape for substance use disorders and mental health conditions. Through its focus on evidence-based practices, regulatory compliance, and integration with traditional healthcare systems, Pear is committed to improving patient outcomes and providing support to both patients and healthcare providers.
Segments
1. Digital Therapeutics for Substance Use Disorders (SUD)
- Pear Therapeutics is particularly known for its innovative approaches to treating substance use disorders. The company utilizes prescription digital therapeutics (PDTs) that can be integrated into traditional care, thereby improving clinical outcomes.
2. Mental Health and Behavioral Disorders
- Beyond substance use disorders, Pears portfolio extends into other areas of mental health, focusing on conditions such as depression and anxiety. Through their digital platforms, they offer behavioral interventions that can complement pharmacological treatments.
3. Regulatory and Clinical Development
- The company is involved in the rigorous clinical testing of its digital products to ensure they meet the necessary regulatory standards. This segment is crucial for gaining FDA approval and other regulatory clearances, enabling the products to be prescribed by healthcare professionals.
Products
1. reSET®
- This is one of Pears flagship products, aimed at treating patients with substance use disorders. reSET is a prescription digital therapeutic that helps patients engage in cognitive behavioral therapy (CBT) and supports recovery through contingency management and continuous connectivity with healthcare providers. It is designed to be used alongside other treatments, such as counseling or medication.
2. reSET-O®
- Similar to reSET, reSET-O is specifically designed for patients suffering from Opioid Use Disorder (OUD). It is intended to provide prescription-level support as part of a comprehensive treatment plan, including medication-assisted treatment (MAT). reSET-O facilitates engagement and allows providers to monitor patient progress through data collected by the software.
3. Pears Digital Therapeutics for Depression
- The company is actively developing products targeted at depression, utilizing evidence-based therapeutic techniques that are delivered through an app-based platform. These digital therapeutics focus on self-management of symptoms and adherence to treatment plans.
4. Next-Generation Digital Therapeutics
- Pear is also exploring further innovations in its product pipeline, which may include therapies for anxiety, insomnia, and other behavioral health conditions. These products are expected to incorporate advanced therapeutic techniques and personalized feedback mechanisms to enhance user experience and engagement.
Services
1. Patient Support Programs
- Pear Therapeutics offers support services to patients using their digital therapeutics. These programs typically include educational resources, reminders for therapy engagement, and access to peer support groups, all designed to enhance the recovery journey.
2. Healthcare Provider Training
- To ensure that healthcare providers can effectively incorporate Pears digital therapeutics into their treatment plans, the company provides training and resources. This service allows healthcare professionals to better understand digital therapies, how to use them alongside traditional treatments, and how to engage with patients effectively.
3. Data Analytics and Reporting
- Pears products often include robust data collection and analytics features that allow healthcare providers to monitor patient progress and treatment engagement effectively. This service can be critical for tailoring treatments and interventions to individual patient needs.
4. Integration with EHR Systems
- Pear is also focused on enabling its therapeutic platforms to integrate seamlessly with electronic health records (EHR) systems. This integration supports the holistic management of patient care and ensures that healthcare providers can easily access relevant data.
Conclusion
Pear Therapeutics Inc. stands at the forefront of the digital therapeutics industry, developing innovative products that transform the treatment landscape for substance use disorders and mental health conditions. Through its focus on evidence-based practices, regulatory compliance, and integration with traditional healthcare systems, Pear is committed to improving patient outcomes and providing support to both patients and healthcare providers.